Colorectal Cancer | Specialty

Dr. Manji on Treatment for Right-Sided Tumors in CRC

September 4th 2019

Gulam A. Manji, MD, PhD, discusses the difference between right- and left-sided tumors in colorectal cancer and the appropriate treatment for right-sided tumors based on a subgroup analysis.

Dr. Lenz on the Safety Profile in CheckMate-142 Trial in CRC

August 28th 2019

Heinz-Josef Lenz, MD, FACP, discusses the safety profile of nivolumab plus ipilimumab in the phase II CheckMate-142 trial for treatment-naïve patients with microsatellite instability–high/mismatch repair deficient colorectal cancer.

Frontline Nivolumab/Ipilimumab Combo Shows Robust Activity in MSI-H/dMMR mCRC

August 23rd 2019

The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer.

Regorafenib/Nivolumab Combo Elicits Responses in CRC and Gastric Cancer

August 21st 2019

Shota Fukuoka, MD, PhD, discusses the results of the study evaluating regorafenib and nivolumab in patients with previously treated gastric and colorectal cancers.

Dr. Lee on Data Regarding HIPEC in mCRC

August 20th 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate clinical professor of surgical oncology, Department of Surgery, and surgical oncologist, City of Hope, discusses data regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC).

ctDNA Testing Now Valuable Tool in CRC, Next Steps Underway

August 20th 2019

Pashtoon M. Kasi, MBBS, MD, MS, discusses the use of ctDNA testing throughout treatment for patients with colorectal cancer and ongoing research on liquid biopsies.

Dr. Manji on Treatment for BRAF-Mutant CRC

August 16th 2019

Gulam A. Manji, MD, PhD, discusses clinical trials for patients with colorectal cancer harboring BRAF or other molecular abnormalities.

Dr. Mizrahi on Encouraging Trial Findings in mCRC

August 15th 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses encouraging trial findings in metastatic colorectal cancer (mCRC).

Dr. Iveson on the IDEA Collaboration in CRC

August 14th 2019

Tim Iveson, MD, FACP, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.

Dr. Hochster on the Safety Analysis of TAS-102 in CRC and Gastric/GEJ Cancer

August 8th 2019

Howard Hochster, MD, FACP, associate director for clinical research and director, Gastrointestinal Oncology, Rutgers Cancer Institute of New Jersey, director of oncology research, RWJBarnabas Health, discusses the safety analysis of TAS-102 in metastatic colorectal cancer and metastatic gastric/gastroesophageal junction cancer.

Dr. Lieu Discusses the Rationale for Combined MEK/VEGF/PD-1 Inhibition in CRC

August 8th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses the rationale for combined MEK, VEGF, and PD-1 inhibition in microsatellite stable (MSS) colorectal cancer (CRC).

Dr. Messersmith on the Need for Biomarkers to Distinguish Between VEGF Inhibitors in CRC

August 7th 2019

Wells A. Messersmith, MD, co-leader of the Developmental Therapeutics Program, and director, GI Cancer Program, and professor of medicine, at the University of Colorado School of Medicine, discusses the need for biomarkers to distinguish between VEGF inhibitors in colorectal cancer (CRC).

Dr. Kasi on the Use of Liquid Biopsies in CRC

August 2nd 2019

Pashtoon M. Kasi, MBBS, MD, MS, hematologist, internist, oncologist, Mayo Clinic, discusses the comparison of circulating tumor DNA tests, tissue, and liquid biopsies, in a study of patients with colorectal cancer.

Novel Therapies for BRAF+ Colorectal Cancer

July 31st 2019

Treating BRAF+ Colorectal Cancer

July 31st 2019

Targeting BRAF and MEK in Colorectal Cancer

July 31st 2019

BRAF Mutations in Colorectal Cancer

July 31st 2019

Emerging Treatment Strategies for Advanced BRAF+ Melanoma

July 31st 2019

Sequencing Therapy in Metastatic BRAF+ Melanoma

July 31st 2019

Selecting Therapy & Managing Patients With BRAF+ Melanoma

July 31st 2019